Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Health related quality of life in SCALOP, a randomized phase II trial comparing chemoradiotherapy regimens in locally advanced pancreatic cancer (LAPC)

Hurt, Chris Nicholas, Mukherjee, Somnath, Bridgewater, John, Falk, Stephen, Crosby, Tom, McDonald, Alec, Joseph, George, Staffurth, John Nicholas, Abrams, Ross A., Blazeby, Jane M., Bridges, Sarah, Dutton, Peter, Griffiths, Gareth, Maughan, Tim and Johnson, Colin 2015. Health related quality of life in SCALOP, a randomized phase II trial comparing chemoradiotherapy regimens in locally advanced pancreatic cancer (LAPC). International Journal of Radiation Oncology*Biology*Physics 93 (4) , pp. 810-818. 10.1016/j.ijrobp.2015.08.026

[img]
Preview
PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Purpose/Objective(s) Chemoradiotherapy (CRT) for patients with LAPC provides survival benefits but may result in considerable toxicity. Health-related quality of life (HRQL) measures during CRT have not been widely reported. This paper reports HRQL data from the SCALOP trial, including validation of the QLQ-PAN26 tool in CRT. Methods and Materials Patients with locally advanced, inoperable, non-metastatic carcinoma of the pancreas were eligible. Following 12 weeks of induction gemcitabine plus capecitabine (GEMCAP) chemotherapy, patients with stable/responding disease were randomised to a further cycle of GEMCAP followed by capecitabine or gemcitabine based CRT. HRQL was assessed with the EORTC QLQ-C30 and PAN26. Results 114 patients from 28 UK centres were registered and 74 patients randomized. There was improvement in the majority of the HRQL scales during induction chemotherapy. Significant deterioration in fatigue, appetite loss, and gastrointestinal symptoms during CRT recovered within 3 weeks following CRT. Differences in changes in HRQL scores between trial arms rarely reached statistical significance, however where they did, they favoured capecitabine. PAN26 scales had good internal consistency and were able to distinguish between subgroups of patients experiencing toxicity Conclusions Although there is deterioration in HRQL following CRT this resolves within 3 weeks. HRQL data support the use of capecitabine over gemcitabine-based chemoradiation. The QLQ-PAN26 is a reliable and valid tool to use in patients receiving CRT.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Elsevier
ISSN: 0360-3016
Date of First Compliant Deposit: 30 March 2016
Date of Acceptance: 13 August 2015
Last Modified: 30 Oct 2017 11:35
URI: http://orca.cf.ac.uk/id/eprint/76623

Citation Data

Cited 13 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics